ADRB1 as a Potential Target for Gene Therapy of Pregnancy Induced Hypertension and Gestational Diabetes Mellitus

Wieclawek, Agnieszka; Sławska, Helena; Mazurek, Urszula

doi:10.3109/10641963.2010.532265

Cited by 6 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Placental transfer of amino acids is essential for fetal growth. Moreover, ADRB1 may be a novel marker for VCT, which has been established as a potential target in GDM (33). The localization of these proteins in cells was confirmed by immunofluorescence analysis (Figure 2C).…”

Section: Single-cell Transcriptome Profiling Of Trophoblast Cells In Gdmmentioning

confidence: 69%

Transcriptomic Profiling of Human Placenta in Gestational Diabetes Mellitus at the Single-Cell Level

et al. 2021

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is associated with an increased risk of adverse pregnancy outcomes. Increasing evidence shows that placentation defects may play important roles in GDM. However, our understanding of the human placenta remains limited. In this study, we generated a comprehensive transcriptomic profile of cellular signatures and transcriptomes in the human placenta in GDM using single-cell RNA sequencing (scRNA-seq), constructed a comprehensive cell atlas, and identified cell subtypes and subtype-specific marker genes. In addition, we investigated the placental cellular function and intercellular interactions in GDM. These findings help to elucidate the molecular mechanisms of GDM, and may facilitate the development of new approaches to GDM treatment and prevention.

show abstract

Section: Single-cell Transcriptome Profiling Of Trophoblast Cells In Gdmmentioning

confidence: 69%

Transcriptomic Profiling of Human Placenta in Gestational Diabetes Mellitus at the Single-Cell Level

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As we summarized in Aim 1, previous studies consistently show evidence of adrenergic receptor expression within the fetoplacental vasculature (Fig. 3), suggesting that agonist-activated adrenergic receptor pathways may alter vascular tone in the fetoplacental circulation [40,44,48,49,52,55–83].…”

Section: Methodsmentioning

confidence: 52%

“…As summarized in Figure 3 , there is evidence showing that all adrenergic receptor subtypes are expressed in the human fetoplacental vasculature. The majority of studies have been conducted using HUVECs or whole placental homogenates, and reported the expression of α 1A , α 1B , α 1D , α 2A , α 2B , α 2C [ 58 , 63 , 69 , 70 ] and β 1 , β 2 and β 3 adrenergic receptor subtypes [ 58 , 73 , 74 , 76 , 79 ], without clarifying the locus or the vessel type [ 70 , 73 , 74 , 76 ] and with a likely high background expression from trophoblast cells [ 69 ]. α 2A appears to be the only adrenergic receptor subtype identified in both endothelial cells and VSMCs within the blood vessels of stem, intermediate and terminal villi [ 69 ].…”

Section: Methodsmentioning

confidence: 99%

Fetoplacental vascular effects of maternal adrenergic antihypertensive and cardioprotective medications in pregnancy

Tropea,

Mavichak,

Evangelinos

et al. 2023

Journal of Hypertension

View full text Add to dashboard Cite

Maternal cardiovascular diseases, including hypertension and cardiac conditions, are associated with poor fetal outcomes. A range of adrenergic antihypertensive and cardioprotective medications are often prescribed to pregnant women to reduce major maternal complications during pregnancy. Although these treatments are not considered teratogenic, they may have detrimental effects on fetal growth and development, as they cross the fetoplacental barrier, and may contribute to placental vascular dysregulation. Medication risk assessment sheets do not include specific advice to clinicians and women regarding the safety of these therapies for use in pregnancy and the potential off-target effects of adrenergic medications on fetal growth have not been rigorously conducted. Little is known of their effects on the fetoplacental vasculature. There is also a dearth of knowledge on adrenergic receptor activation and signalling within the endothelium and vascular smooth muscle cells of the human placenta, a vital organ in the maintenance of adequate blood flow to satisfy fetal growth and development. The fetoplacental circulation, absent of sympathetic innervation, and unique in its reliance on endocrine, paracrine and autocrine influence in the regulation of vascular tone, appears vulnerable to dysregulation by adrenergic antihypertensive and cardioprotective medications compared with the adult peripheral circulation. This semi-systematic review focuses on fetoplacental vascular expression of adrenergic receptors, associated cell signalling mechanisms and predictive consequences of receptor activation/deactivation by antihypertensive and cardioprotective medications.

show abstract

“…The pink module was identified with a weak, although significant correlation to islet amyloidosis ( r = 0.3), which included 20 genes recognized as hub genes for their strong correlation to the module eigengene. Table 5 lists these genes, out of which four were previously reported in relation to T2D and pancreatic beta cells: ARDB1, FXYD3, F13A1 and FXYD2 (8–11). None of the module hub genes, including the four mentioned ones, have been previously associated with islet amyloidosis.…”

Section: Resultsmentioning

confidence: 99%

Identification of a unique transcriptomic signature associated with islet amyloidosis

Barovic

Steinmeyer

Kipke

et al. 2022

Preprint

View full text Add to dashboard Cite

Aims: This cross-sectional study aims to identify potential transcriptomic changes conveyed by presence of amyloid deposits in islets from pancreatic tissue obtained from metabolically profiled living donors. Methods: After establishing Thioflavin S as the most sensitive approach to detect islet amyloid plaques, we utilized RNA sequencing data obtained from laser capture microdissected islets to define transcriptomic effects of this pathological entity. The RNA sequencing data was used to identify differentially expressed genes by linear modeling. Further analyses included functional enrichment analysis of KEGG and Hallmark gene sets as well as a weighted gene correlation network analysis. Results: Eleven differentially expressed genes were identified in islets affected by amyloidosis. Enrichment analyses pointed to signatures related to protein aggregation diseases, energy metabolism and inflammatory response. A gene co-expression module was identified that correlated to islet amyloidosis. Conclusion: Although the influence of underlying Type 2 diabetes could not be entirely excluded, this study presents a valuable insight into the biology of islet amyloidosis, particularly providing hints into the potential relationship between islet amyloid deposition and structural and functional proteins involved in insulin secretion. Keywords: pancreatic islet amyloidosis, transcriptomics, protein aggregation, Type 2 diabetes, metabolically phenotyped living donors

show abstract

ADRB1 as a Potential Target for Gene Therapy of Pregnancy Induced Hypertension and Gestational Diabetes Mellitus

Cited by 6 publications

References 13 publications

Transcriptomic Profiling of Human Placenta in Gestational Diabetes Mellitus at the Single-Cell Level

Transcriptomic Profiling of Human Placenta in Gestational Diabetes Mellitus at the Single-Cell Level

Fetoplacental vascular effects of maternal adrenergic antihypertensive and cardioprotective medications in pregnancy

Identification of a unique transcriptomic signature associated with islet amyloidosis

Contact Info

Product

Resources

About